We are live on ! Find out more
NVIV

InVivo Therapeutics Holdings Corp
NVIV

Delisted

NVIV was delisted on the 12th of February, 2024.

Back to rankings

18 hedge funds and large institutions have $720K invested in InVivo Therapeutics Holdings Corp in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

13% more funds holding

Funds holding: 16 → 18 (+2)

2% more capital invested

Capital invested by funds: $706K → $720K (+$13.7K)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
18
Holders Change
+2
Holders Change %
+12.5%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$557K
2
TRCT
Tower Research Capital (TRC)
New York
+$8.51K
3
Morgan Stanley
Morgan Stanley
New York
+$78
4
Wells Fargo
Wells Fargo
California
+$10
5
CTA
Colonial Trust Advisors
South Carolina
+$5

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$184K
2
Two Sigma Investments
Two Sigma Investments
New York
-$49K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$45K
4
Renaissance Technologies
Renaissance Technologies
New York
-$44.1K
5
UBS Group
UBS Group
Switzerland
-$3.19K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$522K +$557K +222,000 New
BlackRock
2
BlackRock
New York
$81.6K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$39.8K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$26K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$24K -$44.1K -17,600 -63%
TRCT
6
Tower Research Capital (TRC)
New York
$12K +$8.51K +3,395 +194%
UBS Group
7
UBS Group
Switzerland
$10K -$3.19K -1,273 -23%
Morgan Stanley
8
Morgan Stanley
New York
$3.52K +$78 +31 +2%
IA
9
IFP Advisors
Florida
$1K -$3 -1 -50%
Wells Fargo
10
Wells Fargo
California
$31 +$10 +4 +44%
CTA
11
Colonial Trust Advisors
South Carolina
$5 +$5 +2 New
FFA
12
Farther Finance Advisors
California
$5 +$5 +2 New
TF
13
TimeScale Financial
Massachusetts
$4 – – –
SWM
14
Sugarloaf Wealth Management
Georgia
$2 – – –
CA
15
CoreCap Advisors
Michigan
$2 +$3 +1 New
Citadel Advisors
16
Citadel Advisors
Florida
– -$184K -42,794 Closed
Two Sigma Investments
17
Two Sigma Investments
New York
– -$49K -11,521 Closed
Two Sigma Advisers
18
Two Sigma Advisers
New York
– -$45K -10,468 Closed
Royal Bank of Canada
19
Royal Bank of Canada
Ontario, Canada
– -$3 -1 -1%
JP Morgan Chase
20
JP Morgan Chase
New York
– +$3 +1 New

NVIV Hedge Fund Activity: Q4 2022 in Review

18 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q4 2022, worth a combined $720K — up 1.9% from $706K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new NVIV positions and 3 closed out — a net gain of 2 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $557K. The largest seller was Citadel Advisors, exiting entirely with an estimated $184K sold.

  • 18 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q4 2022, up from 16 in Q3 2022.
  • Funds reported $720K of InVivo Therapeutics Holdings Corp stock for Q4 2022, up 1.9% quarter-over-quarter.
  • 5 funds opened new InVivo Therapeutics Holdings Corp positions in Q4 2022 and 3 closed out, a net change of +2 holders.
  • The largest InVivo Therapeutics Holdings Corp buyer in Q4 2022 was Armistice Capital, an estimated $557K added.
  • The largest InVivo Therapeutics Holdings Corp seller in Q4 2022 was Citadel Advisors, an estimated $184K sold.

Based on aggregated 13F filings for Q4 2022.